Understand the source comparison
Retatrutide 30s Age-Specific Protocol: Side Effect Comparison
20–29 4mg weekly 22–28% 10–12mg weekly 88–92% Higher baseline NEAT and GH secretion allow faster titration with lower GI impact. Standard protocols work well 30–39 2mg weekly 15–20% (with 6-week titration) 6–8mg weekly 90–94% Age-adjusted slow titration levera
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 20–29
- 4mg weekly
- 22–28%
- 10–12mg weekly
- 88–92%
- Higher baseline NEAT and GH secretion allow faster titration with lower GI impact. Standard protocols work well
- 30–39
- 2mg weekly
- 15–20% (with 6-week titration)
- 6–8mg weekly
- 90–94%
- Age-adjusted slow titration leverages residual insulin sensitivity while avoiding GI cascade. Ideal metabolic window
- 40–49
- 32–38%
- 10–14mg weekly
- 82–86%
- Declining insulin sensitivity requires higher doses, but reduced GI tolerance creates narrow therapeutic window
- 50+
- 4–6mg weekly
- 38–45%
- 12–16mg weekly
- 78–82%
- Metabolic adaptation and reduced receptor sensitivity demand higher dosing. Lean mass loss becomes primary concern